Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 771 items
  • 1
  • 2
  • 3
  • ...
  • 52
  • >>
  1. Stocks

    Celgene, Acceleron Launch Blood Disorder Study (CELG)

    Acceleron and Celgene are launching an ambitious trial to find a cure for a cancer-like blood disorder that will eliminate the need for blood transfusions.
  2. Stocks

    Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE)

    Rivals Kite and Novartis are both racing to market their leukemia drug first.
  3. Stocks

    Amgen Rolls Out Kidney Disease Campaign (AMGN)

    The BloodCounts campaign aims to provide moral support to patients and caregivers, along with sharing of vital information.
  4. Stocks

    Celgene Buys Blood Cancer Specialist Acetylon (CELG)

    Cash-rich Celgene expanded its cancer drug portfolio with the purchase of Boston-based Acetylon Pharmaceuticals.
  5. Stocks

    Hepatitis C Drugs Could Reactivate Hep B (GILD)

    Following last month’s FDA warning, EU regulators have warned that some hepatitis C drugs could reactivate hepatitis B in some patients.
  6. Stocks

    Amgen, Allergan File for Avastin Biosimilar in EU (AGN)

    Amgen and Allergan are all set to grab a slice of billion-dollar cancer drug market with their ABP 215 biosimilar.
  7. Stocks

    Genetic Technologies Launches ADS Offering (GENE)

    Genetic Technologies expects to raise more than $6 million through an offering of its American Depositary Shares.
  8. Stocks

    Heat Biologics Bladder Cancer Drug Fizzles (HBTX)

    Heat Biologics could discontinue its bladder cancer drug program after it failed a mid-stage study.
  9. Stocks

    Aradigm Lung Infection Antibiotic Fails Trial (ARDM)

    Aradigm reported mixed study results for its inhaled antibiotic for lung disease.
  10. Stocks

    Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH)

    At long last! Sarepta's muscular dystrophy drug Exondys 51 finally got coverage by UnitedHealth insurance.
  11. Stocks

    Teleflex To Acquire Vascular Solutions for $1B (TFX)

    Medical device maker Vascular Solutions finds a timely buyer, after its CEO was found not guilty in a criminal lawsuit.
  12. Stocks

    Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO)

    Biogen’s spinoff Bioverativ remains on track for public listing in early 2017, and gets two key hemoglobinopathy programs from Sangamo.
  13. Stocks

    Biogen MS Drug Sued for Patent Infringement (BIIB)

    Biogen’s multiple sclerosis drug Tecfidera, which accounts for one-third of the company’s revenue, is up for a patent challenge.
  14. Stocks

    Inovio Wins $6.1M Zika Drug Development Grant (INO)

    Inovio continues to lead the race to fight Zika, and received a grant from the Wistar Institute to develop a cure.
  15. Stocks

    Xencor's 4.6M-Share Offering Priced at $24 (XNCR)

    Xencor expects to raise $110 million from its public offering of 4.6 million common shares.
  • Showing 1-15 of 771 items
  • 1
  • 2
  • 3
  • ...
  • 52
  • >>